IL21 and neoplasm: Here, we engineered an anti-PD-1 antibody-based immunocytokine, denoted as PD-1Ab21, by fusing IL-21 to anti-PD-1 diabody to illustrate that cytokines can be targeted to tumor-reactive T cells in vivo to promote cancer immunotherapy.